vs

Side-by-side financial comparison of Ceribell, Inc. (CBLL) and Kestrel Group Ltd (KG). Click either name above to swap in a different company.

Ceribell, Inc. is the larger business by last-quarter revenue ($24.8M vs $17.4M, roughly 1.4× Kestrel Group Ltd). Kestrel Group Ltd runs the higher net margin — -29.0% vs -54.6%, a 25.6% gap on every dollar of revenue.

Ceribell, Inc. develops and commercializes innovative portable neurodiagnostic medical devices, focused on rapid non-invasive electroencephalogram (EEG) solutions for seizure detection. Its core products serve hospital emergency departments, intensive care units, and long-term care facilities, with primary markets across North America and ongoing global expansion efforts.

Kestrel is an American bicycle brand which specialized in high-end bikes for triathlons and road racing.

CBLL vs KG — Head-to-Head

Bigger by revenue
CBLL
CBLL
1.4× larger
CBLL
$24.8M
$17.4M
KG
Higher net margin
KG
KG
25.6% more per $
KG
-29.0%
-54.6%
CBLL

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
CBLL
CBLL
KG
KG
Revenue
$24.8M
$17.4M
Net Profit
$-13.5M
$-5.1M
Gross Margin
87.3%
Operating Margin
-58.9%
-23.3%
Net Margin
-54.6%
-29.0%
Revenue YoY
Net Profit YoY
EPS (diluted)
$-0.35
$-0.65

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CBLL
CBLL
KG
KG
Q4 25
$24.8M
Q3 25
$22.6M
$17.4M
Q2 25
$21.2M
$5.6M
Q1 25
$20.5M
Q3 24
$17.2M
Net Profit
CBLL
CBLL
KG
KG
Q4 25
$-13.5M
Q3 25
$-13.5M
$-5.1M
Q2 25
$-13.6M
$69.9M
Q1 25
$-12.8M
Q3 24
$-10.4M
Gross Margin
CBLL
CBLL
KG
KG
Q4 25
87.3%
Q3 25
88.3%
Q2 25
88.1%
Q1 25
87.9%
Q3 24
87.3%
Operating Margin
CBLL
CBLL
KG
KG
Q4 25
-58.9%
Q3 25
-64.8%
-23.3%
Q2 25
-70.5%
Q1 25
-69.3%
Q3 24
-57.8%
Net Margin
CBLL
CBLL
KG
KG
Q4 25
-54.6%
Q3 25
-59.6%
-29.0%
Q2 25
-64.4%
1258.8%
Q1 25
-62.4%
Q3 24
-60.6%
EPS (diluted)
CBLL
CBLL
KG
KG
Q4 25
$-0.35
Q3 25
$-0.37
$-0.65
Q2 25
$-0.38
$15.05
Q1 25
$-0.36
Q3 24
$-1.85

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CBLL
CBLL
KG
KG
Cash + ST InvestmentsLiquidity on hand
$159.3M
$12.9M
Total DebtLower is stronger
$174.1M
Stockholders' EquityBook value
$155.3M
$143.8M
Total Assets
$195.8M
$1.1B
Debt / EquityLower = less leverage
1.21×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CBLL
CBLL
KG
KG
Q4 25
$159.3M
Q3 25
$168.5M
$12.9M
Q2 25
$177.4M
$19.0M
Q1 25
$182.7M
Q3 24
$14.1M
Total Debt
CBLL
CBLL
KG
KG
Q4 25
Q3 25
$174.1M
Q2 25
$173.8M
Q1 25
Q3 24
Stockholders' Equity
CBLL
CBLL
KG
KG
Q4 25
$155.3M
Q3 25
$164.1M
$143.8M
Q2 25
$172.2M
$150.1M
Q1 25
$180.9M
Q3 24
$-136.0M
Total Assets
CBLL
CBLL
KG
KG
Q4 25
$195.8M
Q3 25
$199.5M
$1.1B
Q2 25
$207.7M
$1.2B
Q1 25
$213.5M
Q3 24
$47.1M
Debt / Equity
CBLL
CBLL
KG
KG
Q4 25
Q3 25
1.21×
Q2 25
1.16×
Q1 25
Q3 24

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CBLL
CBLL
KG
KG
Operating Cash FlowLast quarter
$-10.8M
$-9.7M
Free Cash FlowOCF − Capex
$-11.0M
FCF MarginFCF / Revenue
-44.2%
Capex IntensityCapex / Revenue
0.7%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters
$-41.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CBLL
CBLL
KG
KG
Q4 25
$-10.8M
Q3 25
$-11.1M
$-9.7M
Q2 25
$-7.5M
$-20.7M
Q1 25
$-11.4M
Q3 24
Free Cash Flow
CBLL
CBLL
KG
KG
Q4 25
$-11.0M
Q3 25
$-11.5M
Q2 25
$-7.6M
Q1 25
$-11.6M
Q3 24
FCF Margin
CBLL
CBLL
KG
KG
Q4 25
-44.2%
Q3 25
-50.8%
Q2 25
-35.9%
Q1 25
-56.4%
Q3 24
Capex Intensity
CBLL
CBLL
KG
KG
Q4 25
0.7%
Q3 25
1.6%
Q2 25
0.3%
Q1 25
0.7%
Q3 24
Cash Conversion
CBLL
CBLL
KG
KG
Q4 25
Q3 25
Q2 25
-0.30×
Q1 25
Q3 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

CBLL
CBLL

Products$18.8M76%
Subscription$6.0M24%

KG
KG

Segment breakdown not available.

Related Comparisons